Abstract
The optimal schedule for the administration of 5-fluorouracil (5-FU) in the management of advanced colorectal cancer remains to be determined. It has been suggested that this drug may be given by the subcutaneous route and that following a short infusion the bioavailability is similar to that observed after intravenous administration. We report the results we obtained in a patient treated with an intravenous bolus of 5-FU followed by a 22-h subcutaneous infusion. In this patient the bioavailability of 5-FU given by subcutaneous infusion was 0.94. The steady-state plasma levels of 5-FU reached during subcutaneous infusion were comparable with those achieved during intravenous infusion. Following four cycles of subcutaneous therapy, painless blistering was noted at the infusion sites, which healed following the cessation of subcutaneous therapy. Further studies are required to evaluate this route of therapy as an alternative to protracted intravenous therapy. The main dose-limiting side effect appears to be local skin toxicity.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 27 August 1995 / Accepted: 16 November 1995
Rights and permissions
About this article
Cite this article
Eatock, M., Carlin, W., Dunlop, D. et al. Bioavailability of subcutaneous 5-fluorouracil: a case report. Cancer Chemother Pharmacol 38, 110–112 (1996). https://doi.org/10.1007/s002800050456
Issue Date:
DOI: https://doi.org/10.1007/s002800050456